Ui-Soon Khoo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8234676/publications.pdf Version: 2024-02-01

	101543	114465
4,662	36	63
citations	h-index	g-index
133	133	7397
docs citations	times ranked	citing authors
	4,662 citations 133 docs citations	4,662 36 citations h-index 133 133 docs citations 133 times ranked

LILSOON KHOO

#	Article	IF	CITATIONS
1	To IPAS or not to IPAS? Examining the construct validity of the Interprofessional Attitudes Scale in Hong Kong. Journal of Interprofessional Care, 2022, 36, 127-134.	1.7	2
2	Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer. Life, 2022, 12, 93.	2.4	4
3	Androgen Receptor as an Emerging Feasible Biomarker for Breast Cancer. Biomolecules, 2022, 12, 72.	4.0	18
4	Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer. Cancers, 2022, 14, 1251.	3.7	11
5	What characterize high and low achieving teams in Interprofessional education: A self-determination theory perspective. Nurse Education Today, 2022, 112, 105321.	3.3	2
6	What factors facilitate interprofessional collaboration outcomes in interprofessional education? A multi-level perspective. Nurse Education Today, 2022, 114, 105393.	3.3	4
7	A Case of Primary Hepatic Neuroendocrine Tumor and Literature Review. Case Reports in Oncology, 2021, 14, 90-97.	0.7	4
8	Targeting the IL-6/STAT3 Signalling Cascade to Reverse Tamoxifen Resistance in Estrogen Receptor Positive Breast Cancer. Cancers, 2021, 13, 1511.	3.7	22
9	Clinicopathologic features of primary intraosseous carcinoma in situ arising from odontogenic keratocyst: A case report and literature review. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology, 2021, 33, 354-357.	0.3	0
10	Using Risk Stratification to Optimize Mammography Screening in Chinese Women. JNCI Cancer Spectrum, 2021, 5, pkab060.	2.9	0
11	KPNA1 regulates nuclear import of NCOR2 splice variant BQ323636.1 to confer tamoxifen resistance in breast cancer. Clinical and Translational Medicine, 2021, 11, e554.	4.0	10
12	Repurposing hyperpolarizationâ€activated cyclic nucleotideâ€gated channels as a novel therapy for breast cancer. Clinical and Translational Medicine, 2021, 11, e578.	4.0	7
13	Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants. Nature Communications, 2020, 11, 1217.	12.8	46
14	A Splice Variant of NCOR2, BQ323636.1, Confers Chemoresistance in Breast Cancer by Altering the Activity of NRF2. Cancers, 2020, 12, 533.	3.7	7
15	Phosphorylation independent eIF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer. Oncogene, 2020, 39, 3206-3217.	5.9	18
16	BQ323636.1, a Novel Splice Variant to <i>NCOR</i> 2, as a Predictor for Tamoxifen-Resistant Breast Cancer. Clinical Cancer Research, 2018, 24, 3681-3691.	7.0	23
17	PTEN PDZ-binding domain suppresses mammary carcinogenesis in the MMTV-PyMT breast cancer model. Cancer Letters, 2018, 430, 67-78.	7.2	5
18	Abstract 5903: The molecular mechanism for producing BQ323636.1 in Tamoxifen resistance breast cancer cells. , 2018, , .		0

#	Article	IF	CITATIONS
19	Dual-utility NLS drives RNF169-dependent DNA damage responses. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2872-E2881.	7.1	51
20	BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer. Oncogenesis, 2016, 5, e214-e214.	4.9	28
21	RNF168 cooperates with RNF8 to mediate FOXM1 ubiquitination and degradation in breast cancer epirubicin treatment. Oncogenesis, 2016, 5, e252-e252.	4.9	29
22	OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance. Oncogene, 2016, 35, 1433-1444.	5.9	108
23	Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. Oncogene, 2016, 35, 990-1002.	5.9	167
24	Comparison of fluorescence in-situ hybridisation with dual-colour in-situ hybridisation for assessment of HER2 gene amplification of breast cancer in Hong Kong. Hong Kong Medical Journal, 2016, 22, 144-151.	0.1	7
25	Abstract 4761: Translational regulation by eIF4E and its contribution to tamoxifen resistance in breast cancer. , 2016, , .		0
26	Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer. Oncogenesis, 2015, 4, e167-e167.	4.9	26
27	FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer. Oncogene, 2015, 34, 5012-5024.	5.9	32
28	Prognostic significance of minichromosome maintenance proteins in breast cancer. American Journal of Cancer Research, 2015, 5, 52-71.	1.4	47
29	FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance. Oncogene, 2014, 33, 4144-4155.	5.9	109
30	Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nature Genetics, 2014, 46, 886-890.	21.4	135
31	Innovative use of technologies to enhance the teaching of pathology. Pathology, 2014, 46, S31.	0.6	1
32	Abstract 3334: The role of nuclear HER3 in breast cancer resistance. , 2014, , .		0
33	SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis, 2013, 34, 1476-1486.	2.8	147
34	Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls. Human Molecular Genetics, 2013, 22, 2539-2550.	2.9	86
35	SpliceArray Profiling of Breast Cancer Reveals a Novel Variant of <i>NCOR2/SMRT</i> That Is Associated with Tamoxifen Resistance and Control of <i>ERα</i> Transcriptional Activity. Cancer Research, 2013, 73, 246-255.	0.9	29
36	Nuclear Localization Marker of FOXO3a: Can it be Used to Predict Doxorubicin Response?. Frontiers in Oncology, 2013, 3, 149.	2.8	4

#	Article	IF	CITATIONS
37	Cytoplasmic CXCR4 High-Expression Exhibits Distinct Poor Clinicopathological Characteristics and Predicts Poor Prognosis in Triple-Negative Breast Cancer. Current Molecular Medicine, 2013, 13, 410-416.	1.3	24
38	Genome-Wide Association Study in East Asians Identifies Novel Susceptibility Loci for Breast Cancer. PLoS Genetics, 2012, 8, e1002532.	3.5	137
39	Pathway Analyses Identify <i>TGFBR2</i> as Potential Breast Cancer Susceptibility Gene: Results from a Consortium Study among Asians. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1176-1184.	2.5	22
40	FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene, 2012, 31, 1845-1858.	5.9	131
41	Regarding "Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients― Breast Cancer Research and Treatment, 2012, 131, 351-352.	2.5	5
42	Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16369-16374.	7.1	375
43	The Role of Pea3 Group Transcription Factors in Esophageal Squamous Cell Carcinoma. American Journal of Pathology, 2011, 179, 992-1003.	3.8	14
44	Polyomavirus enhancer activator 3 protein promotes breast cancer metastatic progression through Snailâ€induced epithelial–mesenchymal transition. Journal of Pathology, 2011, 224, 78-89.	4.5	45
45	Replication and Functional Genomic Analyses of the Breast Cancer Susceptibility Locus at 6q25.1 Generalize Its Importance in Women of Chinese, Japanese, and European Ancestry. Cancer Research, 2011, 71, 1344-1355.	0.9	71
46	Genome-wide association study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium. Human Molecular Genetics, 2011, 20, 4991-4999.	2.9	92
47	Constitutively Nuclear FOXO3a Localization Predicts Poor Survival and Promotes Akt Phosphorylation in Breast Cancer. PLoS ONE, 2010, 5, e12293.	2.5	90
48	Significance of the Myxovirus Resistance A (MxA) Gene â''123C>A Singleâ€Nucleotide Polymorphism in Suppressed Interferon β Induction of Severe Acute Respiratory Syndrome Coronavirus Infection. Journal of Infectious Diseases, 2010, 201, 1899-1908.	4.0	31
49	Identification of a Functional Genetic Variant at 16q12.1 for Breast Cancer Risk: Results from the Asia Breast Cancer Consortium. PLoS Genetics, 2010, 6, e1001002.	3.5	107
50	CD209 (DC-SIGN) â^336A>G promoter polymorphism and severe acute respiratory syndrome in Hong Kong Chinese. Human Immunology, 2010, 71, 702-707.	2.4	37
51	Abstract 3156: elF4E in human breast cancer and its role in regulating translation of splice variants of breast cancer genes. , 2010, , .		0
52	Abstract 2040: Identification of microRNAs associated with tamoxifen resistance in breast cancer. Cancer Research, 2010, 70, 2040-2040.	0.9	2
53	A Germline Mutation (A339V) in Thyroid Transcription Factor-1 (TITF-1/NKX2.1) in Patients With Multinodular Goiter and Papillary Thyroid Carcinoma. Journal of the National Cancer Institute, 2009, 101, 162-175.	6.3	105
54	Gynaecological cancers in genetically susceptible women: new thoughts on tubal pathology. Diagnostic Histopathology, 2009, 15, 545-553.	0.4	4

#	Article	IF	CITATIONS
55	Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family. Familial Cancer, 2008, 7, 125-133.	1.9	15
56	DC-SIGN and L-SIGN: the SIGNs for infection. Journal of Molecular Medicine, 2008, 86, 861-874.	3.9	127
5 7	Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis. International Journal of Cancer, 2008, 123, 296-302.	5.1	66
58	Localization of hRad9 in breast cancer. BMC Cancer, 2008, 8, 196.	2.6	6
59	Functional polymorphisms in the BRCA1 promoter influence transcription and are associated with decreased risk for breast cancer in Chinese women. Journal of Medical Genetics, 2008, 46, 32-39.	3.2	27
60	A novel subset of putative stem/progenitor CD34+Oct-4+ cells is the major target for SARS coronavirus in human lung. Journal of Experimental Medicine, 2007, 204, 2529-2536.	8.5	56
61	Association of ICAM3 Genetic Variant with Severe Acute Respiratory Syndrome. Journal of Infectious Diseases, 2007, 196, 271-280.	4.0	33
62	CpG/CpNpG motifs in the coding region are preferred sites for mutagenesis in the breast cancer susceptibility genes. FEBS Letters, 2007, 581, 4668-4674.	2.8	7
63	Reply to "Lack of support for an association between CLEC4M homozygosity and protection against SARS coronavirus infection― Nature Genetics, 2007, 39, 694-696.	21.4	9
64	A retroperitoneal immature teratoma with rhabdomyoblastic and nephroblastic differentiation. Pathology, 2006, 38, 364-367.	0.6	5
65	Microsatellite instability in mitochondrial genome of common female cancers. International Journal of Gynecological Cancer, 2006, 16, 259-266.	2.5	42
66	Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection. Nature Genetics, 2006, 38, 38-46.	21.4	127
67	Effect of all-trans retinoic acid on tissue dynamics of choriocarcinoma cell lines: an organotypic model. Journal of Clinical Pathology, 2006, 59, 845-850.	2.0	7
68	Single nucleotide polymorphisms of follicle-stimulating hormone receptor are associated with ovarian cancer susceptibility. Carcinogenesis, 2006, 27, 1502-1506.	2.8	46
69	Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis. Histopathology, 2005, 46, 307-313.	2.9	54
70	Id helix-loop-helix proteins are differentially expressed in gestational trophoblastic disease. Histopathology, 2005, 47, 303-309.	2.9	14
71	Mcl-1 expression in gestational trophoblastic disease correlates with clinical outcome. Cancer, 2005, 103, 268-276.	4.1	26
72	Subcutaneous Panniculitislike T-Cell Lymphoma Appearing as a Breast Mass. Journal of Ultrasound in Medicine, 2005, 24, 1453-1460.	1.7	22

5

#	Article	IF	CITATIONS
73	Single Nucleotide Polymorphism of Pi-Class Glutathione S-Transferase and Susceptibility to Endometrial Carcinoma. Clinical Cancer Research, 2005, 11, 2981-2985.	7.0	22
74	Epigenetic and genetic alterations of p33 ING1b in ovarian cancer. Carcinogenesis, 2005, 26, 855-863.	2.8	45
75	Promoter Methylation and Differential Expression of ï€-Class Glutathione S-Transferase in Endometrial Carcinoma. Journal of Molecular Diagnostics, 2005, 7, 8-16.	2.8	51
76	Chromosome in situ hybridisation, Ki-67, and telomerase immunocytochemistry in liquid based cervical cytology. Journal of Clinical Pathology, 2004, 57, 721-727.	2.0	19
77	The first batch of graduates of a new medical curriculum in Asia: how their teachers see them. Medical Education, 2004, 38, 980-986.	2.1	11
78	Analysis of gestational trophoblastic disease by genotyping and chromosome in situ hybridization. Modern Pathology, 2004, 17, 40-48.	5.5	60
79	Proliferation to apoptosis ratio as a prognostic marker in adenocarcinoma of uterine cervix. Gynecologic Oncology, 2004, 92, 866-872.	1.4	22
80	Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecologic Oncology, 2004, 93, 435-440.	1.4	80
81	Atypical squamous cells of undetermined significance on cervical smears. Cancer, 2004, 102, 74-80.	4.1	17
82	Metastatic trophoblastic disease after an initial diagnosis of partial hydatidiform mole. Cancer, 2004, 100, 1411-1417.	4.1	46
83	c-mos Immunoreactivity Aids in the Diagnosis of Gestational Trophoblastic Lesions. International Journal of Gynecological Pathology, 2004, 23, 145-150.	1.4	8
84	Analysis of gestational trophoblastic disease by genotyping and chromosome in situ hybridization. Modern Pathology, 2004, 17, 40-48.	5.5	4
85	Liquid-based cytology and conventional cervical smears. Cancer, 2003, 99, 331-335.	4.1	75
86	Detection of mitochondrial DNA mutations in gestational trophoblastic disease. Human Mutation, 2003, 22, 177-177.	2.5	12
87	Minichromosome maintenance protein 7 expression in gestational trophoblastic disease: correlation with Ki67, PCNA and clinicopathological parameters. Histopathology, 2003, 43, 485-490.	2.9	36
88	Challenging and Unusual Cases. Journal of Clinical Oncology, 2003, 21, 1417-1418.	1.6	12
89	A transitional course from high school to medical school in a new medical curriculum in Asia: how do the students see it?*. Medical Teacher, 2003, 25, 89-91.	1.8	3
90	Applications of localized image processing techniques in wireless sensor networks. , 2003, , .		13

#	Article	IF	CITATIONS
91	Coexisting Epithelioid Trophoblastic Tumor and Choriocarcinoma of the Uterus Following a Chemoresistant Hydatidiform Mole. Archives of Pathology and Laboratory Medicine, 2003, 127, e291-e293.	2.5	33
92	Re: Population-Based Case-Control Study of HER2 Genetic Polymorphism and Breast Cancer Risk. Journal of the National Cancer Institute, 2002, 94, 1581-1582.	6.3	6
93	Cervical and Peritoneal Fluid Cytology of Uterine Sarcomas. Acta Cytologica, 2002, 46, 465-469.	1.3	22
94	Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: A founder mutation of BRCA1 identified in the Chinese population. Human Mutation, 2002, 19, 307-308.	2.5	65
95	Malignant placental site trophoblastic tumor. Cancer, 2002, 94, 2288-2294.	4.1	30
96	Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Research, 2002, 62, 4151-6.	0.9	98
97	Apoptotic activity in gestational trophoblastic disease correlates with clinical outcome: assessment by the caspase-related M30 CytoDeath antibody. Histopathology, 2001, 38, 243-249.	2.9	63
98	Primary peritoneal malignant mixed Mïż½llerian tumors. Cancer, 2001, 91, 1052-1060.	4.1	48
99	Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. Cancer, 2001, 91, 949-956.	4.1	121
100	Palpable asymmetrical thickening of the breast: aclinical, radiological and pathological study. British Journal of Radiology, 2001, 74, 402-406.	2.2	1
101	Primary peritoneal malignant mixed Müllerian tumors. Cancer, 2001, 91, 1052-1060.	4.1	3
102	Primary peritoneal malignant mixed MÃ1⁄4llerian tumors. A clinicopathologic, immunohistochemical, and genetic study. Cancer, 2001, 91, 1052-60.	4.1	12
103	Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations. Human Mutation, 2000, 16, 88-89.	2.5	36
104	Collecting duct carcinoma presenting as a bleeding complicated renal cyst. Annals of the College of Surgeons of Hong Kong, 2000, 4, 167-168.	0.0	0
105	Immunohistochemical and mutational analysis of p53 tumor suppressor gene in gestational trophoblastic disease: correlation with mdm2, proliferation index, and clinicopathologic parameters. International Journal of Gynecological Cancer, 1999, 9, 123-130.	2.5	30
106	Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer. Oncogene, 1999, 18, 4643-4646.	5.9	74
107	Collision of Endometrioid Carcinoma and Stromal Sarcoma of the Uterus. International Journal of Gynecological Pathology, 1999, 18, 77-81.	1.4	26
108	Role of Serial Tumor Markers in the Surveillance for Recurrence in Endometrial Cancer. Cancer Detection and Prevention, 1999, 23, 397-400.	2.1	16

#	Article	IF	CITATIONS
109	Pseudomyxoma peritonei - a heterogenous disease. International Journal of Gynecology and Obstetrics, 1998, 62, 173-182.	2.3	19
110	p21WAF1/CIP1 expression in gestational trophoblastic disease: correlation with clinicopathological parameters, and Ki67 and p53 gene expression. Journal of Clinical Pathology, 1998, 51, 159-162.	2.0	37
111	Biologic Markers in Breast Cancer: An Update. Journal of Histotechnology, 1998, 21, 317-325.	0.5	2
112	Cytogenetic study of malignant ovarian germ cell tumors by chromosome in situ hybridization. International Journal of Gynecological Cancer, 1998, 8, 222-232.	2.5	1
113	Ovarian Mature Cystic Teratoma With Malignant Transformation An Interphase Cytogenetic Study. International Journal of Gynecological Pathology, 1998, 17, 351-357.	1.4	20
114	Fine Needle Aspiration Cytology of Myxopapillary Ependymoma. Acta Cytologica, 1998, 42, 1022-1026.	1.3	15
115	Expression of p53 in recurrent nodal metastasis from nasopharyngeal carcinoma (NPC). European Journal of Surgical Oncology, 1997, 23, 415-418.	1.0	11
116	ls immunostaining with HAM56 antibody useful in identifying ovarian origin of metastatic adenocarcinomas?. Human Pathology, 1997, 28, 91-94.	2.0	13
117	Mixed low grade and high grade endometrial stromal sarcoma of uterus: differences on immunohistochemistry and chromosome in situ hybridisation Journal of Clinical Pathology, 1996, 49, 604-607.	2.0	29
118	The expression of cathepsin D, oestrogen receptor and progestogen receptor in hydatidiform mole?an immunohistochemical study. Histopathology, 1995, 27, 341-347.	2.9	11
119	Cholestatic liver cell adenoma in a child with hirsutism and elevated serum levels of cortisol and ACTH. Histopathology, 1994, 25, 586-588.	2.9	8
120	Sudden death associated with bloodless aortic dissection. Forensic Science International, 1993, 59, 149-155.	2.2	13
121	Epstein-Barr virus in carcinoma of the vulva Journal of Clinical Pathology, 1993, 46, 849-851.	2.0	6
122	Fibro-osseous pseudotumor of the digits: report of a case with immunohistochemical and ultrastructural studies. Pathology, 1993, 25, 193-196.	0.6	23
123	Necrolytic Migratory Erythema in Glucagonoma Syndrome. Journal of Dermatology, 1992, 19, 369-374.	1.2	5
124	Gastric carcinoma in young Hong Kong Chinese. Journal of Gastroenterology and Hepatology (Australia), 1992, 7, 343-346.	2.8	1
125	Response from authors. Forensic Science International, 1992, 57, 87-88.	2.2	0
126	Rapid death from thrombotic thrombocytopaenic purpura following caesarean section. Forensic Science International, 1992, 54, 75-80.	2.2	7

#	Article	IF	CITATIONS
127	Intraâ€abdominal desmoplastic small roundâ€cell tumour. Histopathology, 1992, 20, 531-534.	2.9	18
128	Malignant melanoma of the female genital tract A report of nine cases in the Chinese of Hong Kong. Pathology, 1991, 23, 312-317.	0.6	24
129	The utility of ancillary tests in the diagnosis of jaundice. Medical Informatics = Medecine Et Informatique, 1988, 13, 93-104.	0.8	4